首页|人生长激素注射液联合维生素D3治疗矮小症患儿的效果

人生长激素注射液联合维生素D3治疗矮小症患儿的效果

扫码查看
目的:探讨人生长激素注射液联合维生素D3治疗矮小症患儿的效果。方法:选取2022年1月—2023年1月莆田市儿童医院收治的80例矮小症患儿。随机将其分为观察组和对照组,各40例。对照组给予人生长激素注射液,观察组在对照组基础上给予维生素D3。比较两组治疗前后生长发育指标、血清生长因子及25羟基维生素D[25(OH)D]水平、骨代谢指标及不良反应。结果:治疗后,两组身高、体重均升高,观察组身高、体重、生长速度均高于对照组,差异有统计学意义(P<0。05)。治疗后,两组胰岛素样生长因子结合蛋白-3(IGFBP-3)、25(OH)D及胰岛素样生长因子-1(IGF-1)水平均升高,观察组IGFBP-3、25(OH)D及IGF-1水平均高于对照组,差异有统计学意义(P<0。05)。治疗后,两组骨钙素(OC)、骨碱性磷酸酶(BAP)及Ⅰ型前胶原氨基端前肽(PⅠNP)水平均升高,且观察组OC、BAP、PⅠNP水平均高于对照组,差异有统计学意义(P<0。05)。两组不良反应发生率比较,差异无统计学意义(P>0。05)。结论:矮小症患儿采取人生长激素注射液联合维生素D3治疗可调节血清生长因子及25(OH)D水平,改善骨代谢指标,促进生长发育,且未增加不良反应,有较好的安全性。
Effect of Human Growth Hormone Injection Combined with Vitamin D3 in the Treatment of Children with Nanosomia
Objective:To investigate the effect of Human Growth Hormone Injection combined with Vitamin D3 in the treatment of children with nanosomia.Method:A total of 80 children with nanosomia treated in Putian Children's Hospital from January 2022 to January 2023 were selected.They were randomly divided into observation group and control group,40 cases in each group.The control group was given Human Growth Hormone Injection,and the observation group was given Vitamin D3 based on the control group.Growth and development indexes,serum growth factor and 25-hydroxyvitamin D[25(OH)D]levels,bone metabolism indexes before and after treatment and adverse reactions were compared between the two groups.Result:After treatment,the height and weight of both groups increased,and the height,weight and growth rate of the observation group were higher than those of the control group,the differences were statistically significant (P<0.05).After treatment,the levels of insulin-like growth factor binding protein-3 (IGFBP-3),25(OH)D,and insulin-like growth factor-1 (IGF-1) increased in both groups,the levels of IGFBP-3,25(OH)D,and IGF-1 in the observation group were higher than those in the control group,and the differences were statistically significant (P<0.05).After treatment,the levels of osteocalcin (OC),bone alkaline phosphatase (BAP) and amino terminal propeptide of type Ⅰ procollagen (PINP) were increased in both groups,and the levels of OC,BAP and PⅠNP in observation group were higher than those in control group,the differences were statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:Treatment with Human Growth Hormone Injection combined with Vitamin D3 can regulate the levels of serum growth factor and 25(OH)D,improve bone metabolism indexes,promote growth and development without increasing adverse reactions,and has a good safety.

NanosomiaGrowth hormoneVitamin D3Growth factor25-hydroxyvitamin DAdverse reaction

徐源彬、魏凤芳、许金霞

展开 >

莆田市儿童医院 福建 莆田 351100

矮小症 生长激素 维生素D3 生长因子 25羟基维生素D 不良反应

2024

中外医学研究
中国医院管理杂志社

中外医学研究

影响因子:1.149
ISSN:1674-6805
年,卷(期):2024.22(29)